Wilbur J Pan MD PhD

Pediatric Hematology & Oncology•Rahway, NJ

Oncology Clinical Director, Merck & Co.

Merck & Co.126 E. Lincoln Ave.Rahway, NJ 07065
Phone+1 732-594-3082

Dr. Pan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pan's full profile Already have an account?

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Pediatric Hematology/Oncology, 1997 - 2000
University of Texas Southwestern Medical CenterResidency, Pediatrics, 1994 - 1997
University of Illinois College of MedicineClass of 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NJ State Medical License 2000 - 2027
IL State Medical License 1997 - 2002
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.
Amin Haiderali, Linda A Okoth, Srinivas Annavarapu, Jessica K Paulus, Wilbur Pan
Future Oncology. 2026-07-01
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.
Hope S Rugo, David W Cescon, Peter Schmid, Zbigniew Nowecki, Seock-Ah Im
NPJ Breast Cancer. 2026-06-26
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-...
Sherko Kuemmel, Peter A Fasching, Peter Schmid, Nadia Harbeck, Masato Takahashi
Annals of Surgical Oncology. 2026-06-01

Journal Articles

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Javier Cortes, M.D., Ph.D., Hope S. Rugo, M.D., David W. Cescon, M.D., Ph.D., Seock-Ah Im, M.D., Ph.D., Mastura M. Yusof, M.D., Carlos Gallardo, M.D., Oleg Lipatov, M...., New England Journal of Medicine, 7/21/2022
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
Min Huang, Peter Fasching, Amin Haiderali , Wilbur Pan, Emma Gray, Zheng-Yi Zhou, Peter Hu, Mitashri Chaudhuri, Celine Le Bailly De Tilleghem, Nicolas Cappoen & Joyce ..., Immunotherapy, 7/7/2022